Details

Autor(en) / Beteiligte

• McHutchison, John G
• Manns, Michael P
• Muir, Andrew J
• Terrault, Norah A
• Jacobson, Ira M
• Afdhal, Nezam H
• Heathcote, E. Jenny
• Zeuzem, Stefan
• Reesink, Hendrik W
• Garg, Jyotsna
• Bsharat, Mohammad
• George, Shelley
• Kauffman, Robert S
• Adda, Nathalie
• M.D, Adrian M. Di Bisceglie

Titel

Telaprevir for Previously Treated Chronic HCV Infection

Ist Teil von

• The New England journal of medicine, 2010-04, Vol.362 (14), p.1292-1303

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial of patients infected with hepatitis C virus genotype 1 in whom a sustained virologic response was not achieved after initial therapy, patients retreated with peginterferon alfa-2a and ribavirin combined with telaprevir were more likely to have a sustained response than patients retreated with peginterferon alfa-2a and ribavirin alone. Patients retreated with peginterferon alfa-2a and ribavirin combined with telaprevir were more likely to have a sustained response than patients retreated with peginterferon alfa-2a and ribavirin alone. Worldwide, an estimated 170 million people have chronic hepatitis C virus (HCV) infection, and in many of these people, cirrhosis and complications of end-stage liver disease will develop. 1 , 2 Chronic HCV infection is the leading cause of liver disease and is the leading indication for liver transplantation in the United States and Europe. 3 Currently available treatment for HCV infection necessitates peginterferon alfa injections combined with oral ribavirin for 24 or 48 weeks (depending on the HCV genotype). 4 Overall, in 40 to 50% of patients infected with HCV genotype 1 who have not previously been treated, the currently available treatment results . . .